Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials

✍ Scribed by G. R. LICHTENSTEIN; R. H. DIAMOND; C. L. WAGNER; A. A. FASANMADE; A. D. OLSON; C. W. MARANO; J. JOHANNS; Y. LANG; W. J. SANDBORN

• Book ID: 108605651
• Publisher: John Wiley and Sons
• Year: 2009
• Tongue: English
• Weight: 438 KB
• Volume: 30
• Category: Article
• ISSN: 0269-2813
• DOI: 10.1111/j.1365-2036.2009.04027.x